AITBiotech Licenses Multiple Assays | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Singapore genomics service firm AITBiotech announced it has licensed molecular assays developed by research institutes under Singapore's Agency for Science Technology and Research (A*STAR).

The assays were licensed from Exploit Technologies, the marketing and commercialization arm of A*STAR.
The agreement covers dengue/chikungunya multiplex detection kits and a Mycobacterium tuberculosis detection kit. The kits are used with PCR systems.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.